<Objectives>~Primary Objective:~To evaluate the safety and tolerability of MEDI5752 in Japanese subjects with advanced solid tumors.~Secondary Objective:~To assess the anti-tumor activity and efficacy of MEDI5752. To describe the pharmacokinetics of MEDI5752.~Exploratory Objective:~To conduct exploratory research into factors that may be predictive of response or may influence the progression of cancer and/or response (efficacy) to MEDI5752.~Eligible patients will be administered as a single dose at each Cycle Day1. Each cycle from Cycle 1 has a duration of 21 days.~A minimum of 3 and a maximum of 9 evaluable patients will be enrolled in each cohort.
This is a Phase 1, open-label study evaluate the safety, tolerability, pharmacokinetics, immunogenicity and anti-tumor activity of MEDI5752 in Japanese patients with advanced solid solid tumors.